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The application of microseed matrix screening to the crystal-
lization of antibody–antigen complexes is described for a set
of antibodies that include mouse anti-IL-13 antibody C836, its
humanized version H2L6 and an afﬁnity-matured variant of
H2L6, M1295. The Fab fragments of these antibodies were
crystallized in complex with the antigen human IL-13. The
initial crystallization screening for each of the three complexes
included 192 conditions. Only one hit was observed for H2L6
and none were observed for the other two complexes. Matrix
self-microseeding using these microcrystals yielded multiple
hits under various conditions that were further optimized to
grow diffraction-quality H2L6 crystals. The same H2L6 seeds
were also successfully used to promote crystallization of the
other two complexes. The M1295 crystals appeared to be
isomorphous to those of H2L6, whereas the C836crystals were
ina different crystal form. Theseresults are consistent with the
concept that the conditions that are best for crystal growth
may be different from those that favor nucleation. Microseed
matrix screening using either a self-seeding or cross-seeding
approach proved to be a fast, robust and reliable method not
only for the reﬁnement of crystallization conditions but also to
promote crystal nucleation and increase the hit rate.
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1. Introduction
Information on the three-dimensional structure of antibody–
antigen complexes is essential for antibody engineering and
for understanding their mechanism of action. It is recognized
that X-ray crystallography provides the most accurate and
detailed data on protein conformation and interactions. This
method depends on the production of well ordered single
crystals of the macromolecule or complex of interest that
diffract X-rays.
The crystallization of macromolecules has advanced in
recent years with the use of protein engineering to enhance
the crystallizability of proteins (Derewenda, 2004, 2010;
Bolanos-Garcia & Chayen, 2009), the application of fast
screens (Jancarik & Kim, 1991; Stura et al., 1992; Rie `s-Kautt &
Ducruix, 1997; Brzozowski & Walton, 2001; McPherson &
Cudney, 2006) and of the use of robotics, which allows the
screening of a large number of crystallization conditions in a
miniaturized format, reducing the amount of protein needed
(Stevens, 2000; Snook et al., 2000; Weselak et al., 2003; Rupp,
2003). Another major development that advanced the ﬁeld
was the application of various microseeding techniques for
crystal optimization (Stura, 1999; Bergfors, 2003). Seedingexploits the hypothesis that the optimal conditions needed for
crystal nucleation and for crystal growth can be quite different
(Kam et al., 1978). Traditionally, two general approaches,
microseeding and macroseeding, have been used to produce
single crystals of macromolecules (Bergfors, 2003). These
approaches typically use microseeds or macroseeds produced
from the macromolecule of interest. In some cases, seeding
with the crystals of a sequence variant or homologous protein
has proven to be successful (Stura & Wilson, 1991; Walter et
al., 2008). This cross-seeding approach can be used for related
proteins that may include complexes with various ligands,
heavy-atom derivatives and homologous proteins such as the
Fab fragments of monoclonal antibodies (mAbs).
The use of seeding has been extended by the ‘microseed
matrix screening’ (MMS) approach, in which seeds are
systematically transferred into new conditions to promote
crystal growth (Ireton & Stoddard, 2004). The use of MMS has
become an essential part of the screening process in several
laboratories employing self-seeding (D’Arcy et al., 2007) or
cross-seeding with protein derivatives (Walter et al., 2008).
Recently, a study investigating this methodology provided
evidence that in some cases the seed-stabilization solution by
itself can induce crystallization as effectively as the presence
of seeds (St John et al., 2008). Regardless of the underlying
mechanism, the MMS technique has great potential for
improving hit rates in the screening for crystallization condi-
tions.
We have applied the MMS method to the crystallization of
antibody–antigen complexes and report here the successful
crystallization of three IL-13 complexes with different but
related Fab fragments: C836, H2L6 and M1295. C836 is a
mouse hybridoma mAb against human IL-13. The C836 mAb
binds IL-13 with high afﬁnity and blocks the binding of IL-13
to its receptors. The variable (V) regions of this mAb were
chimerized to human G1 and kappa constant regions. This
antibody was further humanized by grafting the comple-
mentarity-determining regions (CDRs) into human variable
framework segments to yield H2L6 mAb. H2L6 was subse-
quently afﬁnity-matured by selection of CDR variants to
produce M1295 mAb (Fransson et al., 2010). In terms of the
amino-acid sequence, H2L6 differs from C836 at 40 positions
in the 228 residues of the variable domains. M1295 differs
from H2L6 at only four positions. All three Fabs contained the
same human constant domains. The crystals of the complexes
were used in their structure determinations, which have been
reported previously (Fransson et al., 2010; the atomic models
were deposited in the PDB under accession codes 3l5w, 3l5x
and 3l5y).
In this paper, we describe a crystallization routine that
includes the following steps: (i) conventional ‘fast screening’
with commercial kits, (ii) selection of hits and preparation of
the seed stock, (iii) MMS in a subset of the initial screen and
(iv) ﬁnal optimization of conditions if needed. Both self-
seeding and cross-seeding proved to be effective in producing
diffraction-quality crystals. Application of the MMS method
increased the hit rate and consequently reduced the numberof
experiments and the amount of protein needed.
2. Materials and methods
2.1. Proteins
Recombinant human IL-13 was purchased from R&D
Systems (Minneapolis, Minnesota, USA; catalog No. 213-IL/
CF). The protein was reconstituted in phosphate-buffered
saline (PBS) pH 7.4 according to the manufacturer’s protocol.
His-tagged C836 Fab was expressed in CHO cells. The H2L6
and M1295 Fabs were prepared by papain cleavage of the
corresponding mAbs. All Fab proteins were puriﬁed using
afﬁnity and size-exclusion chromatography as described
previously (Fransson et al., 2010).
2.2. Complex preparation
For complex formation, puriﬁed C836, H2L6 and M1295
Fab fragments were buffer-exchanged into 20 mM Tris–HCl
pH 7.4, 50 mM NaCl. The complexes were prepared by mixing
each Fab with IL-13 at a Fab:IL-13 molar ratio of 1:1.2 (excess
IL-13). The mixture was incubated for 20 min at 277 K, con-
centrated to a ﬁnal volume of 0.6 ml using an Amicon Ultra
5 kDa device (Millipore) and loaded onto a Superdex 200
10/300 column (GE Healthcare, Piscataway, New Jersey, USA)
equilibrated with 20 mM HEPES pH 7.5, 0.1 M NaCl. A shift
in the elution proﬁle (elution earlier than the free Fab) indi-
cated complex formation. Three runs were performed, with
0.2 ml protein solution applied each time to the column for
each complex. Fractions corresponding to the main peak were
pooled, concentrated to 6–9 mg ml
1 in 20 mM HEPES pH
7.5, 0.1 M NaCl and used in crystallization trials.
2.3. Crystallization screening
Crystallization of the complexes was carried out by the
sitting-drop vapor-diffusion method at 293 K. Screening for
crystallization conditions was carried out using a Hydra II
eDrop robot (Thermo Scientiﬁc, Waltham, Massachusetts,
USA) to set up crystallization trials in 96-well Corning 3550
plates (Corning, New York, USA). The experiments were
composed of 0.5 ml protein solution mixed with an equal
volume of reservoir solution. The droplets were equilibrated
against 90 ml reservoir solution. Optimization screens were
made using a Matrix Maker (Emerald BioSystems, Bainbridge
Island, Washington, USA).
2.4. Seed-stock preparation and microseed matrix screening
Microcrystals used for seed-stock preparation were placed
in 100 ml reservoir solution, homogenized by vortexing for
3 min with a Teﬂon Seed Bead (Hampton Research, Aliso
Viejo, California, USA) and stored at 253 K. The MMS was set
up manually using the hanging-drop vapor-diffusion method
in 24-well VDX greased plates (Hampton Research, Aliso
Viejo, California, USA). In each crystallization drop, 0.6 ml
screening (reservoir) solution and 0.2 ml microseeds were
added to 0.8 ml protein solution. The protein droplets were
equilibrated over 500 ml reservoir solution.
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3.1. Initial crystallization screening
The initial screening was performed with Crystal Screens I
and II, PEG/Ion Screen (Hampton Research, Aliso Viejo,
California, USA) and in-house grid screens: 192 conditions in
total. The in-house screens, PEG 8000/pH and ammonium
sulfate/pH, each containing 24 conditions, were designed in a
small 6  4 matrix format. In these screens the concentration
of the precipitating agent varied from 18 to 34% for PEG 8000
(all PEG concentrations in this paper are given as weight/
volume percentage solutions) and from 1.5 to 2.4 M for
ammonium sulfate versus a pH range of 3.5–10.5. Needle-like
microcrystals of the H2L6 complex were observed in 28%
PEG 8000, 0.1 M MES pH 6.5 (Fig. 1a). The other two com-
plexes did not produce any hits. Optimization of the H2L6
complex crystallization conditions in a standard approach of
reﬁning the PEG 8000 concentration and using various addi-
tives did not improve the original needle-like crystals.
Therefore, the H2L6 complex microcrystals were used as
seeds in the second screening by the microseed matrix method
(Ireton & Stoddard, 2004; D’Arcy et al., 2007) for all three
complexes.
3.2. H2L6 complex
MMS was performed with the Hampton Research PEG/Ion
Screen (48 conditions). This screen was extended by the
addition of eight conditions containing 14–22% PEG 8000 or
1.6–2.4 M ammonium sulfate both in 0.1 M MES pH 6.5,
representing an optimization screen for the H2L6 complex
microcrystals.
Small isometric crystals were observed after 24 h from
PEG/Ion Screen under several conditions, all of which
contained 20% PEG 3350 plus one of the following salts:
0.2 M lithium acetate pH 7.9 (condition No. 24), 0.2 M
ammonium tartrate pH 6.6 (No. 38), 0.2 M ammonium phos-
phate pH 8.0 (No. 44) or 0.2 M ammonium citrate pH 5.1 (No.
48) (Figs. 1b–1e). No crystals were observed in the experi-
ments using the eight additional conditions.
The new crystallization hits were optimized using a
screen composed of the most promising salt/PEG 3350
combinations (24 conditions). The second MMS was
performed with the same seeds, but the seed stock was diluted
ﬁvefold with 30% PEG 8000, MES pH 6.5 to minimize
nucleation events.
X-ray-quality crystals were obtained from 14% PEG 3350,
0.2 M ammonium tartrate, 0.1 M MES pH 6.5 and from 16%
PEG 3350, 0.2 M ammonium citrate, 0.1 M MES pH 6.5. The
crystals appeared within 2 d and reached dimensions of
0.1  0.1  0.3 mm (Figs.1f and 1g). Both conditions produced
the same crystal form. The crystals from ammonium tartrate
diffracted to 1.9 A ˚ resolution and were used for structure
determination. They belonged to the orthorhombic space
group P212121, with unit-cell parameters a = 63.78, b = 73.02,
c = 114.86 A ˚ . The asymmetric unit contained one molecule of
the complex.
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Figure 1
(a) Microcrystals of H2L6 (28% PEG 8000, 0.1 M MES pH 6.5) used for MMS. (b–e) H2L6 crystals after the ﬁrst round of MMS obtained under the
following conditions: (b) 20% PEG 3350, 0.2 M lithium acetate pH 7.9, (c) 20% PEG 3350, 0.2 M ammonium tartrate pH 6.6, (d) 20% PEG 3350, 0.2 M
ammonium phosphate pH 8.0, (e) 20% PEG 3350, 0.2 M ammonium citrate pH 5.1. (f, g) Diffraction-quality H2L6 crystals after the second round of
MMS obtained under the following conditions: (f) 14% PEG 3350, 0.2 M ammonium tartrate, 0.1 M MES pH 6.5, (g) 16% PEG 3350, 0.2 M ammonium
citrate, 0.1 M MES pH 6.5. Scale bars are 0.3 mm in length.3.3. M1295 complex
The optimized H2L6 crystalsobtained from 16% PEG 3350,
0.2 M ammonium citrate, 0.1 M MES pH 6.5 (Fig. 2a) were
used to prepare seeds for the M1295 complex crystallization.
The initial MMS included the 192 crystallization conditions
described above. Crystals were obtained directly from this
screen in the following conditions from PEG/Ion Screen: 20%
PEG 3350, 0.2 M lithium chloride pH 6.8 (condition No. 4;
Fig. 2b), 20% PEG 3350, 0.2 M potassium chloride pH 7.0
(No. 8; Fig. 2c) and 20% PEG 3350, 0.2 M sodium citrate pH
8.3 (No. 46; Fig. 2d). In addition, X-ray-quality crystals grew
from 25% PEG 8000, 0.1 M sodium acetate pH 5.5 (in-house
grid screen; Fig. 2e). The latter conditions were optimized (pH
4.5) to yield crystals of about 0.2  0.2  0.2 mm in 2 d
(Fig. 2f). These crystals diffracted to 2.8 A ˚ resolution and were
used for structure determination. The crystals have the same
space group and nearly identical unit-cell parameters as the
H2L6 crystals that were used as seeds. The space group is
P212121, with unit-cell parameters a = 63.37, b = 72.50,
c = 114.20 A ˚ . The asymmetric unit contains one molecule of
the complex.
3.4. C836 complex
The same cross-seeding stock from the optimized H2L6
crystals was used for the C836 complex crystallization by
MMS. The screen, a subset of the original 192 ‘fast screen’
conditions, included 24 selected conditions from each of the
Hampton PEG/Ion Screen and in-house PEG 8000 grid
screens and was performed at 6 mg ml
1 protein concentra-
tion. Crystal formations of poor quality appeared in several
drops in a range of conditions after 2 d (Figs. 3a and 3b). A
number of drops remained clear. A mixture of these crystals
obtained in different conditions produced a ‘self-seeding’
stock.
Both ‘cross’ and ‘self’ seeds were used in the MMS opti-
mization, in which the protein concentration was 9 mg ml
1.
To minimize the number of experiments, the optimization
screens included only one buffer, 0.1 M HEPES buffer pH 7.5,
and one of the four salts (sodium formate, sodium tartrate,
ammonium citrate, lithium citrate) at 0.2 M concentration in
the presence of 18–22% PEG 3350. X-ray-quality crystals
were obtained in both the self-seeding and the cross-seeding
experiments within 2 d (Figs. 3c–3f). It is worth noting that the
cross-seeds yielded crystals in all four salts, whereas the self-
seeds only gave crystals in ammonium citrate. The seed quality
may be one reason for this difference.
The best cross-seeding conditions were 20% PEG 3350,
0.2 M sodium tartrate, 0.1 M HEPES pH 7.5 (Fig. 3f). The
crystals belonged to the monoclinic space group P21, with
unit-cell parameters a = 76.62, b = 65.56, c = 118.74 A ˚ ,
 = 107.02. The best self-seeding conditions were 18% PEG
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Figure 2
(a) Crystals of H2L6 (20% PEG 3350, 0.2 M ammonium citrate pH 5.1) used to generate a seed stock for MMS crystallization of M1295 and C836. (b–f)
Crystals of M1295 obtained by MMS under the following conditions: (b) 20% PEG 3350, 0.2 M lithium chloride pH 6.8, (c) 20% PEG 3350, 0.2 M
potassium chloride pH 7.0, (d) 20% PEG 3350, 0.2 M sodium citrate pH 8.3, (e) 25% PEG 8000, 0.1 M sodium acetate pH 5.5, (f) 25% PEG 8000, 0.1 M
sodium acetate pH 4.5. Scale bars are 0.2 mm in length.3350, 0.2 M ammonium citrate, 0.1 M HEPES pH 7.5 (Fig. 3c).
These crystals were isomorphous to the cross-seeded crystals.
Both types of crystals diffracted to 2 A ˚ resolution.
4. Discussion
The initial crystallization screening for all three complexes
included 192 conditions from the commercial and in-house
screens. Despite sequence similarities between the complexes,
only one experiment (28% PEG 8000, 0.1 M MES pH 6.5)
with H2L6 produced needle-like crystals. Since a classical
optimization of the conditions for improving these crystals
proved fruitless, we faced a choice of either using these
microcrystals as seeds or extending, perhaps signiﬁcantly, the
initial screening. The latter option would certainly require
much more protein and would not after all guarantee the
result. In contrast, the ﬁrst option proved to be very efﬁcient
and given the variety of successful conditions appears to be
more robust and reliable.
MMS using the initial H2L6 microcrystals was performed in
48 conditions of the standard Hampton PEG/Ion Screen and
in eight additional conditions. Multiple hits amenable to
optimization appeared overnight under a number of condi-
tions that included 20% PEG 3350 and 0.2 M salt with a pH in
the range 5.0–8.0. All drops contained a large number of
crystals, indicating that the seed concentration was too high.
Optimization was achieved by simply diluting the seed stock,
resulting in X-ray-quality crystals from the same PEG/Ion
Screen.
M1295 differs in sequence from H2L6 at only four positions,
none of which are involved in lattice contacts in the H2L6
crystal form that was used for structure determination. Owing
to this similarity, it was not surprising that the M1295 crystals
were isomorphous to the H2L6 crystals. An interesting
observation resulting from these experiments was that the
X-ray-quality crystals of M1295 were obtained from the same
screen that was used unsuccessfully in the initial screening of
this complex. MMS with H2L6 seeds yielded several crystals
suitable for X-ray diffraction studies and a large number of
hits that could be easily optimized by simple seed dilution.
The same MMS procedure was applied to the C836
complex. The amino-acid sequence of C836 differs signiﬁ-
cantly from that of the other two Fabs since C836 contains
mouse variable domains. Despite the differences and the
reduced size of the MMS screen (only 48 conditions), a
number of hits were obtained that could be optimized.
However, conditions that favored the growth of large crystals
were not among the 48 conditions selected for the MMS
screen. A different set of 12 ‘optimized’ conditions based
primarily on the H2L6 results was used with the same seed
stock as before and yielded X-ray-quality crystals. This
experiment showed that although the MMS screen may be less
extensive than the initial ‘nucleation’ screen, it still must
contain a sufﬁcient array of reﬁned conditions to ﬁnd crystal-
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Figure 3
Crystals of C836. (a, b) Microcrystals used to generate a self-seed stock obtained from the following conditions: (a) 25% PEG 8000, 0.1 M HEPES pH
7.5, (b) 20% PEG 3350, 0.2 M lithium citrate pH 8.4. (c–f) Diffraction-quality crystals of C836 obtained by MMS under the following conditions (all
contain 0.1 M HEPES pH 7.5): (c) 18% PEG 3350, 0.2 M ammonium citrate, self-seeds, (d) 20% PEG 3350, 0.2 M ammonium citrate, cross-seeds, (e)
22% PEG 3350, sodium formate, cross-seeds, (f) 20% PEG 3350, 0.2 M sodium tartrate, cross-seeds. Scale bars are 0.2 mm in length.growth conditions. From a practical perspective, to conserve
protein and time we start with a limited set of conditions and
then extend it, if necessary, through additional screens
covering different pH, reagent concentrations or additives.
Besides the reservoir composition, the protein and seed
concentrations are other important parameters that affect
crystal growth. For instance, in the C836 trials some drops
remained clear after several days at a protein concentration of
6m gm l
1 but hits were identiﬁed within 24 h when the
concentration was increased to 9 mg ml
1. In the reﬁnement
step, high protein concentrations in the drop may trigger
additional nucleation or even precipitation and should be
avoided.
In the current application of MMS, we do not have much
control over the seed concentration. However, under condi-
tions where showers of crystals appeared, dilution of the seed
stock was carried out in order to reduce the number of crystals
in each drop. This was a key factor in H2L6 crystallization
optimization. Conversely, the seed concentration in the ﬁrst
round of C836 MMS was not high enough. The desired
concentration was achieved by combining and mixing seeds
from different conditions. The use of the frozen seed stock
ensured constant seed concentration and reproducibility of
the experiments. We did not notice any decrease in seed
concentration after repeated freeze–thaw cycles as judged by
the number of crystals in the drop.
The introduction of seeds into the crystallization droplet
increased the hit rate in all three cases described in this report.
The effect was particularly noticeable for M1295 and C836, for
which no hits were obtained from the initial screening. After
MMS, crystals of various quality were observed in 18 of 192
conditions for M1295 and in seven of 24 conditions for C836.
The question remains whether the seeds themselves or the
seed-stabilization solution cause the effect. In our experi-
ments, the dilution of the seed stock with the same stabiliza-
tion solution reproducibly decreased the number of crystals in
the drops. This may be the strongest argument supporting the
role of seeds in nucleation.
Although published results with MMS have described the
self-seeding protocol (D’Arcy et al., 2007; Baumgartner et al.,
2009) and cross-seeding with protein derivatives (Walter et al.,
2008), there may be no restriction to the composition of the
cross-seeds used to promote crystal growth. The crystallization
of the C836 complex is an example of successful cross-seeding
with a different protein in a different crystal form.
H2L6 and C836 have identical constant domains but
different variable domains. The H2L6 crystals are ortho-
rhombic (space group P212121, unit-cell parameters a =6 4 ,
b = 73, c = 115 A ˚ ). The C836 crystals are monoclinic (space
group P21, unit-cell parameters a = 77, b= 66, c= 119 A ˚ ). Both
forms have approximately the same packing density, with VM
values of 2.23 A ˚ 3 Da
1 for H2L6 and 2.35 A ˚ 3 Da
1 for C836.
Analysis of intermolecular contacts in these crystals revealed
one type of contact that is common to both crystal forms: a
-bridge between the light and heavy chains of contacting
Fabs. This interaction yields a row of Fab molecules linked
through their constant domains (Fig. 4). Interactions involving
the variable domains and IL-13 are quite different in the two
crystal forms. It is possible that the interactions between the
constant domains formed the basis of the crystal lattice that
served as a nucleus for the cross-seeded crystal growth.
In conclusion, MMS proved to be a fast, easy and reliable
method for reﬁnement of crystallization conditions. Once the
initial conditions have been established, the numberof crystals
in the drop may be controlled by dilution of the seed stock,
which often is sufﬁcient to obtain large crystals. In our
experience, the MMS method promotes crystal nucleation and
increases the hit rate, thus reducing the size of the initial
crystallization screen and saving time and protein. In some
cases, MMS produces crystal forms that differ from those of
the seeds. Further experiments may determine whether a
‘universal’ seed stock can produce enough hits for a given
protein or class of protein whose members have signiﬁcant
sequence homology, such as Fabs.
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